Suppr超能文献

经胸骨切开术后新发持续性阿片类药物使用的发生率。

The Incidence of New Persistent Opioid Use Following Cardiac Surgery via Sternotomy.

机构信息

Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Division of Cardiac Surgery, Yale School of Medicine, New Haven, Connecticut.

出版信息

Ann Thorac Surg. 2022 Jan;113(1):33-40. doi: 10.1016/j.athoracsur.2021.04.030. Epub 2021 Apr 27.

Abstract

BACKGROUND

In recent years, increased attention has turned toward the risk of chronic opioid use after surgery. In this nationwide cohort study, we examined the rate of new persistent opioid use after cardiac surgery by sternotomy.

METHODS

All opioid-naive patients undergoing heart surgery by sternotomy from 2005 to 2018 in Iceland were included in the study. Naivety was defined as not filling an opioid prescription within 6 months before surgery. Persistent opioid use was defined as filling at least 1 opioid prescription during the first 90 days after surgery and another 90 to 180 days after the operation. In addition to estimating the incidence of new persistent opioid use, differences in patient characteristics, survival, and readmission rates were compared between the group with and without new persistent opioid use.

RESULTS

Of 1227 patients who underwent cardiac surgery by sternotomy during the study period, 925 were included in the study. Of those, 4.6% developed new persistent opioid use. When only patients who filled an opioid prescription after surgery were included, 10.1% developed new persistent opioid use. Chronic obstructive pulmonary disease, preoperative use of nonsteroidal anti-inflammatory drugs, gabapentinoids, and nitrates were associated with increased risk for new persistent opioid use. Patients with new persistent opioid use did not have higher rates of readmission nor all-cause mortality.

CONCLUSIONS

The rate of new persistent opioid use after cardiac surgery was 4.6%. Future steps should identify strategies to minimize the development of new persistent opioid use.

摘要

背景

近年来,人们越来越关注手术后长期使用阿片类药物的风险。在这项全国性队列研究中,我们通过胸骨切开术研究了心脏手术后新的持续性阿片类药物使用的发生率。

方法

研究纳入了 2005 年至 2018 年期间在冰岛接受胸骨切开术心脏手术的所有阿片类药物初治患者。初治定义为手术前 6 个月内未开阿片类药物处方。持续性阿片类药物使用定义为术后 90 天内至少开 1 次阿片类药物处方,术后 90 至 180 天内再开 1 次阿片类药物处方。除了估计新的持续性阿片类药物使用的发生率外,还比较了有和无新的持续性阿片类药物使用的患者特征、生存率和再入院率的差异。

结果

在研究期间接受胸骨切开术心脏手术的 1227 例患者中,925 例纳入研究。其中,4.6%的患者出现新的持续性阿片类药物使用。当仅纳入术后开阿片类药物处方的患者时,10.1%的患者出现新的持续性阿片类药物使用。慢性阻塞性肺疾病、术前使用非甾体抗炎药、加巴喷丁类药物和硝酸盐与新的持续性阿片类药物使用风险增加相关。使用新的持续性阿片类药物的患者再入院率和全因死亡率均无升高。

结论

心脏手术后新的持续性阿片类药物使用的发生率为 4.6%。未来应采取措施确定策略,尽量减少新的持续性阿片类药物使用的发生。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验